Position of the Transparency Council – Jemperli (dostarlimab)
At its meeting on 14 October 2024, the Transparency Council adopted position No. 108/2024 on the evaluation of the drug Jemperli (dostarlimab) under the drug program “Treatment of patients with endometrial cancer (ICD-10 C54)”
Publication of the position >>